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Background and aims: Both bile salts and glutathione participate in the generation of canalicular bile
flow. In this work, we have investigated the effect of different bile salts on hepatic glutathione metabo-
lism.
Methods: Using the isolated and perfused rat liver, we studied hepatic glutathione content, and
metabolism and catabolism of this compound in livers perfused with taurocholate, ursodeoxycholate,
or deoxycholate.
Results: We found that in livers perfused with ursodeoxycholate, levels of glutathione and the activity
of methionine adenosyltransferase (an enzyme involved in glutathione biosynthesis) were significantly
higher than in livers perfused with other bile salts. In ursodeoxycholate perfused livers, methionine
adenosyltransferase showed a predominant tetrameric conformation which is the isoform with highest
activity at physiological concentrations of substrate. In contrast, the dimeric form prevailed in livers per-
fused with taurocholate or deoxycholate. The hepatic activities of γ-glutamylcysteine synthetase and
γ-glutamyltranspeptidase, enzymes involved, respectively, in biosynthetic and catabolic pathways of
glutathione, were not modified by bile salts.
Conclusions: Ursodeoxycholate specifically enhanced methionine adenosyltransferase activity and
hepatic glutathione levels. As glutathione is a defensive substance against oxidative cell damage, our
observations provide an additional explanation for the known hepatoprotective effects of
ursodeoxycholate.
Glutathione is a tripeptide involved in a diversity ofhepatocellular metabolic pathways. It has been shownthat glutathione is the main promoter of the bile salt
independent fraction of canalicular flow.1 In addition,
glutathione is the principal intracellular defence of the liver
against oxidative stress.2 The biosynthetic pathway of this
compound has two main characteristics: the availability of
cysteine and synthesis of glutathione from this amino acid.3
Cysteine can be obtained from the diet, from methionine
(through the transsulphuration pathway), or as a subproduct
of glutathione catabolism.4
In the conversion of cysteine to glutathione, the limiting
enzyme is γ-glutamylcysteine synthetase (γ-GCS) which is
controlled by negative feedback from its end product
glutathione5 whereas the formation of cysteine involves
several reactions in the named methionine cycle. This cycle
begins with incorporation of an ATP molecule to methionine
to form S-adenosylmethionine (AdoMet) in an irreversible
reaction catalysed by the enzyme methionine adenosyltrans-
ferase (MAT).6 In mammals, AdoMet is mainly used in trans-
methylation reactions7 that produce S-adenosylhomocysteine.
This metabolite is converted to homocysteine which either
rapidly enters the transsulphuration pathway to yield
glutathione or it is used for resynthesis of methionine.8
It has been shown that in the liver there is a close relation-
ship between glutathione content and MAT activity,9–11
suggesting that this enzyme plays an important role in hepatic
glutathione metabolism. In the liver, MAT can be found in two
isoforms, MAT I and MAT III, which are the tetramer and
dimer forms, respectively, of the same polypeptide subunit.12
These two isoforms have different kinetic properties and total
MAT activity in the liver depends critically on the relative con-
tent of each.12
In the present study, we have investigated the effect of bile
salts on hepatic glutathione metabolism in the isolated and
perfused rat liver. Our data show that in contrast with other
bile salts, ursodeoxycholic acid (UDC) specifically increases
liver glutathione content by stimulating hepatic MAT activity.
This paper provides evidence for a novel mechanism which
contributes towards explaining the known hepatoprotective
actions of UDC.
MATERIAL AND METHODS
Bile salts, ATP, methionine, glutathione reductase, bovine
serum albumin, L-∝-aminobutyrate, pyruvate kinase, lactate
dehydrogenase, and NADH were obtained from Sigma
Chemical Co. (St Louis, Missouri, USA). [2-3H]ATP (25.5
Ci/mmol) was purchased from Amersham (Little Chalfont,
UK). NYTRAN membranes were from Schleicher and Schuell
(Keene, New Hampshire, USA). All other chemicals were of
analytical reagent grade and were purchased from Merck
(Darmstadt, Germany).
Livers from male Wistar rats (245–260 g body weight) were
isolated and perfused in a recirculating anterograde way. The
technique for liver isolation has been previously described.13
Briefly, after abdominal laparotomy the liver was exposed, and
both the bile duct and portal vein were cannulated. The liver
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was perfused in situ with oxygenated Krebs-Ringer bicarbo-
nate buffer to eliminate all blood components and the thoracic
vena cava was then cannulated. After transferring the liver to
an acrylic platform, it was placed in a thermostat controlled
and humidified acrylic chamber, and perfused at 30 ml/min
with 250 ml of Krebs-Ringer bicarbonate buffer containing:
116 mM NaCl, 4.7 mM KCl, 1.2 mM KH2PO4, 1 mM MgSO4,
1.25 mM CaCl2, 25 mM NaHCO3, 5 mM glucose, 0.2 mM pyru-
vate, 2 mM lactate, and 1% bovine serum albumin. Immedi-
ately after the beginning of perfusion, a continuous infusion
of different bile salts was initiated and maintained during the
120 minutes of the experiments. The perfusion medium was
continuously gassed with 95% O2/5% CO2, pH was automati-
cally maintained at 7.35–7.40 with an automatic autoburette
(Radiometer, Copenhagen, Denmark), and perfusion pressure
was monitored (Letica pressure transducer, Barcelona, Spain).
Animals were treated humanely and study protocols were
approved by the ethics committee of animal experimentation
of our institution.
We established three experimental groups in which 40
µmol/h of taurocholate (TC, n=5), ursodeoxycholate (UDC,
n=6), or deoxycholate (DC, n=4) were infused for 120
minutes. The dose of 40 µmol/h was chosen on the basis of the
studies of Gores et al in which they found that this rate was
suitable to maintain bile flow in the isolated rat liver.14 To test
the effect of higher doses of TC, UDC, or DC, the study was
repeated with 60 µmol/h of these bile salts in three additional
groups of animals (n=4 for each group). All bile produced in
10 minute intervals from minute 0 onwards was collected in
preweighed polypropylene tubes containing 70 µl of 3% meta-
phosphoric acid to reduce spontaneous oxidation of gluta-
thione in bile,15 and samples of hepatic effluent were obtained
every 30 minutes. At the end of the experiments, several frag-
ments of each liver were rapidly frozen and stored at −80°C
until use.
The viability of the livers during the experiments was
assessed by measuring aspartate aminotransferase (AST) and
lactate dehydrogenase (LDH) in the effluent perfusate. Bile
flow was calculated by gravimetry (assuming a bile density of
1), and total bile salts in bile and in the perfusate were quan-
tified by the 3α-hydroxysteroid dehydrogenase method. Total
glutathione in bile, hepatic effluent, and hepatic tissue was
measured by the method of Tietze,16 with minor modifications.
Perfusate levels of AST and LDH, and γ-glutamyltranspepti-
dase (γ-GT) activity in the livers were measured by conven-
tional enzymatic methods, using a Cobas Fara analyser (Roche
Diagnostics, Basel, Switzerland).
The hepatic biosynthetic pathway of glutathione was evalu-
ated by measuring the activities of γ-GCS and MAT. For deter-
mination of hepatic γ-GCS activity, the liver tissue was
homogenised (1:5) in 0.2 M Tris HCl buffer, pH 8.0, using an
Ultraturrax tissue tearer (IKA Labortechnik, Staufen, Ger-
many) at 22 000 rpm for 30 seconds on ice. Enzyme activity
was measured following the method described by Seelig and
Meister.17 Briefly, 50 µl of tissue homogenate were added to a
1 ml incubation mixture containing 0.1 M Tris HCl buffer, 150
mM KCl, 5 mM Na2ATP, 2 mM phosphoenolpyruvate, 10 mM
L-glutamate, 10 mM L-∝-aminobutyrate, 20 mM MgCl2, 2 mM
Na2-EDTA, 0.2 mM NADH, 17 µg of pyruvate kinase, and 17 µg
of LDH, and the decrease in absorbance at 340 nm was
followed. A control assay was performed by omission of L-∝-
aminobutyrate in the presence of tissue sample. Enzyme
activity was expressed as nmol NADH/min/mg protein.
Protein was determined by the pyrogallol red-molybdate
method18 using a Cobas Mira analyser (Roche Diagnostics,
Basel, Switzerland).
Liver samples (about 1 g) used for determination of MAT
activity were homogenised with a Potter-Elvehjem apparatus
in four volumes of ice cold 10 mM Tris HCl (pH 7.5) contain-
ing 0.3 M sucrose with 0.1% β-mercaptoethanol, 1 mM benza-
midine, and 0.1 mM phenylmethylsulphonyl fluoride. The
homogenate was centrifuged at 12 500 g for 20 minutes at 4°C,
and the supernatant was centrifuged again at 105 000 g for 60
minutes at 4°C.19 The supernatant was used to quantify MAT
activity as described previously.19 Also, a possible direct effect
of bile salts on MAT activity was tested by using purified MAT
III20 in the presence of 30 or 500 µM of TC, UDC, or DC.
For northern blot analysis, total liver RNA was isolated by
the guanidinium thiocyanate method.21 Aliquots (20 µg) of
total RNA were denatured at 65°C for five minutes in 5% for-
maldehyde, 50% formamide, 8% glycerol, and then size
fractionated by electrophoresis (20 mA, 15 hours) in a 0.9%
agarose gel under denaturing conditions. RNAs were then
blotted and fixed to NYTRAN membranes. Prehybridisation
and hybridisation were carried out as described previously.22
MAT mRNA levels were measured using a 2.2 kb EcoRI cDNA
fragment of rat liver MAT.23 mRNA levels of inducible nitric
oxide synthase (iNOS) were determined using a 0.8 kb EcoRI/
HindIII fragment from the macrophage iNOS cDNA.24 Mn
superoxide dismutase (MnSOD) mRNA levels were deter-
mined using a 0.8 kb EcoRI/HindIII fragment from rat liver
cDNA (generous gift of Dr D Massaro, Georgetown University,
Washington DC, USA). Equal loading of the RNA gels was
assessed by hybridisation with a probe specific for β-actin.25
For determination of MAT protein levels, liver samples were
homogenised in four volumes of ice cold 10 mM Tris/HCl (pH
7.5) containing 0.3 M sucrose, 0.1% β-mercaptoethanol, and
protease inhibitors, as above. The homogenate was centri-
fuged for one hour at 100 000 g. Protein concentration was
measured in the supernatants by the method of Bradford,26
and equal amounts of protein (30 µg) were subjected to 10%
sodium dodecyl sulphate-polyacrylamide gel electrophoresis
(SDS-PAGE). Proteins were electrophoretically transferred to
nitrocellulose membranes in a buffer containing 25 mM Tris,
192 mM glycine, and 20 % (vol/vol) methanol. Membranes
were blocked overnight with 1% low fat dry milk in Tris buff-
ered saline containing 0.05% Tween 20. Immunodetection of
MAT was performed using a rabbit anti-MAT antiserum27 and
Figure 1 Bile flow (A) and biliary bile salt excretion (B) over the
course of the experiments in livers continuously infused with 40
µmol/h of taurocholate (TC; n=5), ursodeoxycholic acid (UDC; n=6),
or deoxycholic acid (DC; n=4). Values are mean (SEM).
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a horseradish peroxidase conjugated secondary antibody.
Blots were developed by enhanced chemiluminescence ac-
cording to the manufacturer’s instructions (Dupont, Boston,
Massachusetts, USA).
In order to evaluate the relative content of MAT I and MAT
III, 200 mg of liver tissue were homogenised in 1 ml of the
same buffer described above for determination of levels of
MAT protein. Homogenates were centrifuged at 100 000 g for
one hour and the supernatants (1 ml) were loaded onto 5 ml
disposable polypropylene columns containing 1 ml bed
volume of phenyl-Sepharose CL-4B equilibrated in buffer A
(10 mM HEPES/Na (pH 7.5) with 1 mM EDTA and 10 mM
MgSO4). MAT I and MAT III were eluted from the
phenyl-Sepharose column as previously described.27 Briefly,
MAT I was recovered in the flow through fraction (total
volume of 4 ml) and after washing the column with 8 ml
buffer A, MAT III was eluted with 4 ml of buffer A containing
50% dimethyl sulphoxide. Aliquots of the MAT I eluate (0.5
ml) were lyophilised and resuspended in 100 µl of 1×
SDS-PAGE loading buffer. In parallel, 50 µl of the dimethyl
sulphoxide fraction (MAT III) (total volume 4 ml) were
diluted with 50 µl of the 2× loading buffer. Then, 40 µl of each
preparation were analysed by SDS-PAGE and anti-MAT
antibody immunoblotting, as described above.
Statistical comparisons between experimental groups were
performed by the Mann-Whitney, Wilcoxon, and Kruskal-
Wallis non-parametric tests.28 Values are expressed as mean
(SEM).
RESULTS
As observed in fig 1, bile flow and biliary bile salt excretion
during the experimental period were similar in livers perfused
with 40 µmol/h of TC, UDC, or DC and concentrations of bile
salts in the perfusate were also comparable in the three groups
(TC 12.72 (4.03); UDC 14.39 (2.91); and DC 17.72 (3.27) µM;
NS). Likewise, liver viability, assessed by release into the efflu-
ent of AST, LDH, and glucose, was not significantly different
between the groups (fig 2). Levels of oxygen uptake were also
similar in all groups (TC 2.12 (0.09); UDC 2.24 (0.03); and DC
1.96 (0.08) µmol/min/g liver; NS), and were adequate to
maintain sufficient oxygen consumption.29 Finally, perfusion
pressure at the beginning of perfusion was similar in all
groups, and was maintained without significant changes dur-
ing the experimental period (fig 2).
However, when we measured levels of glutathione in
hepatic tissues collected at the end of the experiments, we
Figure 2 Aspartate aminotransferase (GOT), lactate
dehydrogenase (LDH), and glucose levels, and variation in perfusion
pressure during the experimental period (120 minutes) in livers
continuously infused with 40 µmol/h of taurocholate (TC; n=5),
ursodeoxycholic acid (UDC; n=6), or deoxycholic acid (DC; n=4).
Values are mean (SEM).
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Figure 3 Hepatic content of total glutathione at the end of the
experimental period (120 minutes) in livers continuously infused with
40 µmol/h of taurocholate (TC; n=5), ursodeoxycholic acid (UDC;
n=6), or deoxycholic acid (DC; n=4). Values are mean (SEM).
Statistically significant differences are indicated.
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Figure 4 (A) Biliary excretion of glutathione during the
experimental period in livers perfused with 40 µmol/h of
taurocholate (TC; n=5), ursodeoxycholate (UDC; n=6), or
deoxycholate (DC; n=4). Values are mean (SEM) of biliary excretion
of glutathione in the previous 30 minutes. (B) Sinusoidal efflux of
glutathione. Bars represent mean (SEM) glutathione release to the
hepatic effluent during the experimental period (120 minutes) in the
same groups as before.
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observed a significant increase in glutathione content in livers
perfused with UDC compared with TC or DC perfused livers
(fig 3). As shown in fig 4, higher values of glutathione in UDC
perfused livers were not due to differences in biliary excretion
(fig 4A) or in the sinusoidal efflux of this compound (fig 4B).
In addition, hepatic catabolism of glutathione, as estimated by
γ-GT activity, was similar in the three experimental groups
(36.1 (11.0), 37.5 (2.7), and 31.1 (8.3) mU/g liver, respectively,
in TC, UDC, and DC groups; NS). To gain insight into the
mechanisms responsible for the increased values of gluta-
thione in livers perfused with UDC, we analysed the activity of
the two main enzymes involved in glutathione synthesis,
γ-GCS5 and MAT,8 in tissue samples collected at the end of the
experiments. We observed no significant differences in hepatic
γ-GCS activity among the groups (30.5 (5.5), 27.8 (5.0), and
21.9 (7.3) nmol/mg prot/min, in TC, UDC, and DC groups,
respectively; NS) while MAT activity was significantly
increased in livers perfused with UDC compared with the
other groups (p<0.05) (fig 5). This increase in MAT activity
was more pronounced when the livers were perfused with 60
µmol/h of bile salts. In parallel, UDC perfused livers showed a
higher hepatic content of glutathione with respect to the other
groups (see table 1).
To test whether the observed rise in MAT activity was a con-
sequence of increased MAT gene expression, levels of MAT
mRNA and MAT protein were measured in all experimental
groups. As shown in fig 6, no significant changes were
observed between these groups with respect to both MAT
mRNA and MAT protein levels, as determined by northern
and western blots, respectively.
As both MAT activity and glutathione levels were affected
by reactive nitrogen and oxygen species,30 31 we determined
mRNA levels of iNOS and MnSOD, two enzymes implicated in
the generation and metabolism of NO and O2
−, respectively, as
markers of oxidative and nitrosative stress in the different
groups of livers. No significant changes were found in levels of
these transcripts in the three experimental groups (data not
shown), suggesting that variations in liver glutathione content
and MAT activity induced by UDC are not due to an effect on
oxygen or nitrogen free radical production.
Also, we investigated whether UDC could exert a direct
effect on the activity of purified MAT in vitro. To verify this, the
effect of increasing concentrations of TC, UDC, or DC was
tested and compared with samples in which no bile salts were
added. As can be seen in table 2, when the bile salt concentra-
tion increases, MAT activity decreases, independently of the
bile salt used, although this effect was more evident in the
samples in which DC was used. Nevertheless, at concentra-
tions similar to those found in hepatocytes (that is, in the
range 30–60 µM),32 no statistically significant differences were
found between groups.
To analyse the mechanisms underlying the enhanced MAT
activity in livers which received UDC infusion, we quantified
the relative proportions of MAT I and MAT III in the three
groups of livers by immunoblotting after separation of the two
MAT isoenzymes using phenyl-Sepharose CL-4B
chromatography.27 As shown in fig 7A, the relative proportions
of MAT I and MAT III were similar in TC and DC perfused liv-
ers. In contrast, in livers perfused with UDC, we observed an
increase in the tetrameric isoform (MAT I) and a reduction in
the dimeric isoform (MAT III), resulting in a marked decrease
in the MAT III/MAT I ratio (4.5 (0.5) in the UDC group v 10 (4)
and 14 (4) arbitrary units in TC and DC perfused livers,
respectively; p<0.05). A representative immunoblot of MAT
isoforms obtained from the cytosolic fraction of livers
corresponding to the three experimental groups is shown in
fig 7B.
Figure 5 Hepatic activity of methionine adenosyltransferase (MAT)
at the end of the experimental period (120 minutes) in livers perfused
with 40 µmol/h of taurocholate (TC; n=5), ursodeoxycholate (UDC;
n=6), or deoxycholate (DC; n=4). Values are mean (SEM).
Statistically significant differences are indicated.
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Table 1 Effect of bile salt infusion on liver methionine
adenosyltransferase (MAT) activity and liver
glutathione content
Bile salt infused
TC UDC DC
MAT activity†
Infusion rate
40 µmol/h 150.7 (5.1) 284.9 (13.3)* 103.8 (9.5)
60 µmol/h 162.6 (15.8) 328.4 (81.1)* 109.8 (21.9)
Glutathione content‡
Infusion rate
40 µmol/h 6.22 (0.15) 7.53 (0.24)* 5.21 (0.53)
60 µmol/h 6.49 (1.3) 10.02 (1.0)* 5.52 (0.8)
†Values are expressed as pmol/min/mg protein.
‡Values are expressed as µmol/g liver.
Livers were infused for 120 minutes with 40 or 60 µmol/h of
taurocholate (TC; n=5), ursodeoxycholate (UDC; n=6), or
deoxycholate (DC; n=4).
*p<0.05 compared with the other groups with the same infusion rate.
Figure 6 mRNA expression
and protein levels of methionine
adenosyltransferase (MAT) in
livers perfused for 120 minutes
with 40 µmol/h of taurocholate
(TC; n=5), ursodeoxycholate
(UDC; n=6), or deoxycholate
(DC; n=4). Representative
northern and western blots,
respectively, are shown.
Table 2 Effect of bile salts on methionine
adenosyltransferase (MAT) activity in vitro
Bile salt tested
TC UDC DC
Bile salt concn
30 µM 119.8 (11.0) 115.6 (7.9) 101.6 (2.3)
500 µM 102.1 (6.7) 94.5 (1.5) 95.2 (2.7)
2 mM 95.2 (6.4) 79.5 (5.5) 60.9
(12.7)
6.6 mM 79.2 (7.6) 61.7 (2.4) 34.6
(8.1)*
10 mM 73.4 (5.9) 50.5 (5.2) 36.1
(7.9)*
MAT activity was measured in vitro in the presence of increasing
concentrations of the three bile salts studied (taurocholate (TC),
ursodeoxycholate (UDC), or deoxycholate (DC); n=4–6 measurements
at every point).
Results are expressed as percentage with respect to those obtained in
samples in which no bile salts were added.
*p<0.05 with respect to corresponding values in the TC group.
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DISCUSSION
Our data demonstrate that UDC specifically influences the
metabolism of glutathione in the liver. We found that hepatic
glutathione levels were higher in livers perfused with UDC
than in those which received TC or DC. As biliary excretion of
glutathione and release of glutathione to the perfusate were
similar in UDC, TC, and DC groups, the increased stores of this
compound in livers treated with UDC should be due to differ-
ences in glutathione synthesis or catabolism. Our data indicate
that changes in glutathione catabolism are unlikely to
contribute to this effect as the activity of γ-GT, the enzyme
which mediates catabolism of glutathione at the canalicular
level,33 did not differ between groups. In contrast with this
finding, other authors have reported that bile salts affect γ-GT
activity; however, these data were generated with millimolar
concentrations of bile salts in an in vitro model, and no infor-
mation regarding the effect of UDC was reported.34 35
The biosynthetic pathway of glutathione in the liver
involves several enzymes. The most important are γ-GCS,
which is the rate limiting enzyme in the conversion of cysteine
to glutathione,5 and MAT, whose activity, as previously shown,
is closely related to glutathione concentration. Our results
showed that the activity of γ-GCS was similar in all groups.
Concerning MAT, in the liver there are two different
conformations of the enzyme, the tetrameric (MAT I) and
dimeric (MAT III) forms, the former being the most active at
physiological concentrations of substrates.20 UDC favours the
adoption of the tetrameric conformation and increases the
MAT I/MAT III ratio. This effect of UDC could therefore explain
the higher levels of glutathione observed in UDC perfused liv-
ers. In addition, it has been shown that high glutathione con-
centrations increases MAT activity.31 36 Thus increased synthe-
sis of glutathione by enhanced MAT activity could in turn
stimulate this enzyme. Enhanced MAT activity occurred in the
absence of changes in MAT protein or MAT mRNA levels, and
without variations in oxidative or nitrosative status (as
estimated by MnSOD and iNOS mRNA values) in the three
experimental groups studied. Therefore, it seems that UDC
might elevate hepatic glutathione stores by favouring the
tetrameric conformation of MAT, and both effects would
enhance MAT activity. In agreement with our results, Mitsuy-
oshi et al have recently reported that UDC increases levels of
glutathione in hepatocytes in vitro.37 These authors however
did not analyse in their model the activity of MAT, an enzyme
which, as we have shown, appears to be importantly
influenced by UDC in vivo.
Other mechanisms have been postulated to explain the
beneficial effect of UDC, including protection of bile ducts
against injury induced by hydrophobic bile salts38 and stimu-
lation of biliary secretion of toxic compounds.39 Although
these mechanisms cannot be excluded it should be mentioned
that we did not find stimulation of biliary secretion of bile
salts or glutathione in livers perfused with UDC, suggesting
that activation of biliary secretory processes is not a relevant
effect of UDC in our model.
Glutathione is an essential factor in the cell defence against
oxidative insults,2 and substrates for glutathione biosynthesis,
such as AdoMet, have been shown to exert a protective effect
against cholestasis and various forms of liver damage.40–45 As
UDC stimulates the activity of MAT and enhances glutathione
stores in the liver, our data reveal a new mechanism to account
for the known hepatoprotective actions of this bile salt. The
explanation for this unique effect of UDC could be related to
the physicochemical and pharmacological properties of this
bile salt that make it more hydrophilic than other bile salts
tested in our experiments.39
In summary, our results showed that UDC augments the
concentration of glutathione in the liver by enhancing MAT
activity. This effect is an additional mechanism to explain the
ability of UDC to defend the liver against cholestatic damage
and toxic insults.
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